Baxter International Inc. (“Baxter”) has agreed to Hillrom for $10.5 billion ($156 per share) in a deal expected to close in 2022.  After assumption of debt, the total enterprise value of the deal is approximately $12.4 billion.  The deal had been for about a month before it was announced.

According to Baxter’s , the acquisition is expected to lead to  “accelerated product and digital innovation across the care continuum and care settings.” 

Patients increasingly want to receive their care at home or nearby, while hospitals and other care providers are increasingly using digital health technologies to expand access, improve quality and lower costs. Baxter and Hillrom are uniting to meet the challenges of a rapidly evolving global healthcare landscape, while also creating significant value for all the stakeholders we serve.

J.

The deal is the latest in a , including extending a multi-year strategic agreement with Amazon Web Services, and acquiring certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife.

The Hillrom acquisition is the in an already busy year for medical device mergers and acquisitions.  Other notable acquisitions this year include S; ; and Boston Scientific’s acquisitions of surgical business and .  , mergers and acquisitions in the medical device field were on pace to exceed last year’s performance.

The post appeared first on .